These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 19595619)
1. Substrate reduction therapy in juvenile GM2 gangliosidosis. Maegawa GH; Banwell BL; Blaser S; Sorge G; Toplak M; Ackerley C; Hawkins C; Hayes J; Clarke JT Mol Genet Metab; 2009; 98(1-2):215-24. PubMed ID: 19595619 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. Maegawa GH; van Giersbergen PL; Yang S; Banwell B; Morgan CP; Dingemanse J; Tifft CJ; Clarke JT Mol Genet Metab; 2009 Aug; 97(4):284-91. PubMed ID: 19447653 [TBL] [Abstract][Full Text] [Related]
3. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Pastores GM; Barnett NL; Kolodny EH Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246 [TBL] [Abstract][Full Text] [Related]
4. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. Masciullo M; Santoro M; Modoni A; Ricci E; Guitton J; Tonali P; Silvestri G J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S355-61. PubMed ID: 20821051 [TBL] [Abstract][Full Text] [Related]
5. The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression. Deodato F; Procopio E; Rampazzo A; Taurisano R; Donati MA; Dionisi-Vici C; Caciotti A; Morrone A; Scarpa M Metab Brain Dis; 2017 Oct; 32(5):1529-1536. PubMed ID: 28577204 [TBL] [Abstract][Full Text] [Related]
7. Infantile gangliosidoses: Mapping a timeline of clinical changes. Jarnes Utz JR; Kim S; King K; Ziegler R; Schema L; Redtree ES; Whitley CB Mol Genet Metab; 2017 Jun; 121(2):170-179. PubMed ID: 28476546 [TBL] [Abstract][Full Text] [Related]
8. Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat. Sedel F; Chabrol B; Audoin B; Kaphan E; Tranchant C; Burzykowski T; Tourbah A; Vanier MT; Galanaud D J Neurol; 2016 May; 263(5):927-936. PubMed ID: 26984608 [TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics of early juvenile GM2 gangliosidosis: a case report]. Ono H; Sugiura C; Narita A; Ohno K; Saito Y; Maegaki Y; Murakami N; Nanba E No To Hattatsu; 2017 May; 49(3):203-6. PubMed ID: 30113798 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of miglustat in Niemann-Pick C disease: a single centre experience. Ginocchio VM; D'Amico A; Bertini E; Ceravolo F; Dardis A; Verrigni D; Bembi B; Dionisi-Vici C; Deodato F Mol Genet Metab; 2013 Nov; 110(3):329-35. PubMed ID: 23973268 [TBL] [Abstract][Full Text] [Related]
11. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165 [TBL] [Abstract][Full Text] [Related]
12. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Pineda M; Wraith JE; Mengel E; Sedel F; Hwu WL; Rohrbach M; Bembi B; Walterfang M; Korenke GC; Marquardt T; Luzy C; Giorgino R; Patterson MC Mol Genet Metab; 2009 Nov; 98(3):243-9. PubMed ID: 19656703 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. Guffon N; Bin-Dorel S; Decullier E; Paillet C; Guitton J; Fouilhoux A J Pediatr; 2011 Nov; 159(5):838-844.e1. PubMed ID: 21658716 [TBL] [Abstract][Full Text] [Related]
14. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Fecarotta S; Romano A; Della Casa R; Del Giudice E; Bruschini D; Mansi G; Bembi B; Dardis A; Fiumara A; Di Rocco M; Uziel G; Ardissone A; Roccatello D; Alpa M; Bertini E; D'Amico A; Dionisi-Vici C; Deodato F; Caviglia S; Federico A; Palmeri S; Gabrielli O; Santoro L; Filla A; Russo C; Parenti G; Andria G Orphanet J Rare Dis; 2015 Feb; 10():22. PubMed ID: 25888393 [TBL] [Abstract][Full Text] [Related]
15. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease. Pérez-Poyato MS; Gordo MM; Marfa MP Gene; 2012 Sep; 506(1):207-10. PubMed ID: 22750297 [TBL] [Abstract][Full Text] [Related]
16. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Patterson MC; Vecchio D; Prady H; Abel L; Wraith JE Lancet Neurol; 2007 Sep; 6(9):765-72. PubMed ID: 17689147 [TBL] [Abstract][Full Text] [Related]
18. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Pastores GM; Elstein D; Hrebícek M; Zimran A Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546 [TBL] [Abstract][Full Text] [Related]